CancerGuide Diagnostics enters licensing agreement with Duke

Research collaboration will develop individualised cancer treatment decisions.

The agreement provides CancerGuide with exclusive commercial rights to a range of molecular signatures as well as collaborative access to clinical research and new molecular discoveries from the cancer research institution. CancerGuide is expected to use these technologies to develop new clinical diagnostics, alongside its existing agreement with LabCorp, a clinical laboratory network.

"Duke Medicine is dedicated to ensuring that important new medical discoveries are brought into clinical practice. We are very excited about the potential of our partnership with CancerGuide to bring about dramatic advances in the management of cancer treatment," said Robert Taber, vice chancellor of corporate and venture development at Duke University.